Details for New Drug Application (NDA): 021427
NDA 021427 describes CYMBALTA, which is a drug marketed by Lilly and is included in one NDA. Additional details are available on the CYMBALTA profile page.
The generic ingredient in CYMBALTA is duloxetine hydrochloride. There is one drug master file entry for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.
The generic ingredient in CYMBALTA is duloxetine hydrochloride. There is one drug master file entry for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the duloxetine hydrochloride profile page.
Summary for 021427
| Tradename: | CYMBALTA |
| Applicant: | Lilly |
| Ingredient: | duloxetine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021427
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED REL PELLETS;ORAL | Strength | EQ 20MG BASE | ||||
| Approval Date: | Aug 3, 2004 | TE: | RLD: | Yes | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED REL PELLETS;ORAL | Strength | EQ 30MG BASE | ||||
| Approval Date: | Aug 3, 2004 | TE: | RLD: | Yes | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, DELAYED REL PELLETS;ORAL | Strength | EQ 60MG BASE | ||||
| Approval Date: | Aug 3, 2004 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
